Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment

Inclusion Criteria: * Patients aged 18 and older with moderate to severe orbitopathy; * Patients followed in endocrinology with the goal of achieving euthyroidism; * Corticosteroid-resistant patients: patients who have received at least 3 weeks of treatment with 500 mg weekly corticosteroid boluses and have not shown improvement in the clinical activity score (CAS); * Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing or stopping corticosteroid therapy; * Patients with a CAS ≥ 3 or CAS \<3 with moderate to severe orbitopathy (according to EUGOGO); * Patients treated with immunotherapy, biotherapy, or radiotherapy as second-line treatment; * Patients who are not opposed to the reuse of their health data. Exclusion Criteria: * Patients who have undergone bone or fat decompression surgery; * Patients with severe corneal involvement (Grade B or C; NO SPECS classification); * Patients with optic neuropathy (Grade B and C; NO SPECS classification); * Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy; * Patients who have opposed the reuse of their health data.